Mismatch-based delayed thrombolysis: A meta-analysis

Stroke

Volumn 41, Issue 1, 2010, Pages

  Mishra, Nishant K ^a   Albers, Gregory W ^b   Davis, Stephen M ^c   Donnan, Geoffrey A ^c   Furlan, Anthony J ^d   Hacke, Werner ^e   Lees, Kennedy R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Desmoteplase; Mismatch; Perfusion; Thrombolysis

Indexed keywords

ALTEPLASE; DESMOTEPLASE; PLACEBO;

ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; FIBRINOLYTIC THERAPY; HUMAN; IMAGING; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; RECANALIZATION; REPERFUSION; RISK; STATISTICS; STROKE; SYSTEMATIC REVIEW; VALIDATION STUDY;

CLINICAL TRIALS AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 74049115448     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.566869     Document Type: Article

References (48)

1. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007; 369:275-282.
2. Brott T. Thrombolysis for stroke. Arch Neurol. 1996;53:1305-1306.
3. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
4. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
5. Barber PA, Darby DG, Desmond PM, Yang Q, Gerraty RP, Jolley D, Donnan GA, Tress BM, Davis SM. Prediction of stroke outcome with echoplanar perfusion-and diffusion-weighted MRI. Neurology. 1998;51: 418-426.
6. Jansen O, Schellinger P, Fiebach J, Hacke W, Sartor K. Early recanal-isation in acute ischaemic stroke saves tissue at risk defined by MRI. Lancet. 1999;353:2036-2037.
7. Schellinger PD, Jansen O, Fiebach JB, Pohlers O, Ryssel H, Heiland S, Steiner T, Hacke W, Sartor K. Feasibility and practicality of MR imaging of stroke in the management of hyperacute cerebral ischemia. AJNR Am J Neuroradiol. 2000;21:1184-1189.
8. Ostrem JL, Saver JL, Alger JR, Starkman S, Leary MC, Duckwiler G, Jahan R, Vespa P, Villablanca JP, Gobin YP, Vinuela F, Kidwell CS. Acute basilar artery occlusion: diffusion-perfusion MRI characterization of tissue salvage in patients receiving intra-arterial stroke therapies. Stroke. 2004;35:e30-e34.
9. Dafer RM, Biller J. Desmoteplase in the treatment of acute ischemic stroke. Expert Rev Neurother. 2007;7:333-337.
10. Debens T. Technology evaluation: desmoteplase, PAION/Forest. Curr Opin Mol Ther. 2004;6:567-575.
11. Meretoja A, Tatlisumak T. Novel thrombolytic drugs: will they make a difference in the treatment of ischaemic stroke? CNS Drugs. 2008;22: 619-629.
12. Schleuning WD. Vampire bat plasminogen activator DSPA-a-1 (desmoteplase): a thrombolytic drug optimized by natural selection. Haemo-stasis. 2001;31:118-122.
13. Paciaroni M, Medeiros E, Bogousslavsky J. Desmoteplase. Expert Opin Biol Ther. 2009;9:773-778.
14. Bergum PW, Gardell SJ. Vampire bat salivary plasminogen activator exhibits a strict and fastidious requirement for polymeric fibrin as its cofactor, unlike human tissue-type plasminogen activator: a kinetic analysis. J Biol Chem. 1992;267:17726-17731.
15. Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003;34:537-543.
16. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
17. Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, Roine RO, Toni D, Lees KR. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372: 1303-1309.
18. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, Kaste M, Lipka LJ, Pedraza S, Ringleb PA, Rowley HA, Schneider D, Schwamm LH, Leal JS, Sohngen M, Teal PA, Wilhelm-Ogunbiyi K, Wintermark M, Warach S. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8:141-150.
19. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37:1227-1231.
20. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73
21. Petitti DB, ed. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. 2nd Ed. New York; Oxford University Press 2000.
22. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, De Silva DA, Byrnes G, Chalk JB, Fink JN, Kimber TE, Schultz D, Hand PJ, Frayne J, Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299-309.
23. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, Bammer R, Kakuda W, Lansberg MG, Shuaib A, Coplin W, Hamilton S, Moseley M, Marks MP. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006;60:508-517.
24. Olivot JM, Mlynash M, Thijs VN, Kemp S, Lansberg MG, Wechsler L, Schlaug G, Bammer R, Marks MP, Albers GW. Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE). Stroke. 2008;39:2257-2263.
25. Kohrmann M, Schellinger PD. MRI-based thrombolytic therapy in acute stroke: finally, the proof of concept by DEFUSE. Nat Clin Pract Neurol. 2007;3:370-371.
26. Lansberg MG, Thijs VN, Bammer R, Olivot JM, Marks MP, Wechsler LR, Kemp S, Albers GW. The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion. Stroke. 2008;39: 2491-2496.
27. Kakuda W, Lansberg MG, Thijs VN, Kemp SM, Bammer R, Wechsler LR, Moseley ME, Marks MP, Albers GW. Optimal definition for PWI/DWI mismatch in acute ischemic stroke patients. J Cereb Blood Flow Metab. 2008;28:887-891.
28. Lansberg MG, Thijs VN, Bammer R, Kemp S, Wijman CA, Marks MP, Albers GW. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke. 2007;38:2275-2278.
29. Olivot JM, Mlynash M, Thijs VN, Kemp S, Lansberg MG, Wechsler L, Bammer R, Marks MP, Albers GW. Optimal Tmax threshold for predicting penumbral tissue in acute stroke. Stroke. 2009;40:469-475.
30. Kakuda W, Abo M. Intravenous administration of a tissue plasminogen activator beyond 3 hours of the onset of acute ischemic stroke-MRI-based decision making. Brain Nerve. 2008;60:1173-1180.
31. Kidwell CS, Warach S. Mismatch and DEFUSE: harvesting the riches of multicenter neuroimaging-based stroke studies. Stroke. 2007;38: 1718-1719.
32. Lansberg MG, Thijs VN, Hamilton S, Schlaug G, Bammer R, Kemp S, Albers GW. Evaluation of the clinical-diffusion and perfusion-diffusion mismatch models in DEFUSE. Stroke. 2007;38:1826-1830.
33. Toth G, Albers GW. Use of MRI to estimate the therapeutic window in acute stroke: is perfusion-weighted imaging/diffusion-weighted imaging mismatch an EPITHET for salvageable ischemic brain tissue? Stroke. 2009;40:333-335.
34. Schellinger PD. EPITHET: failed chance or new hope? Lancet Neurol. 2008;7:286-287.
35. Sandercock P, Wardlaw J, Dennis M, Lindley R, Hankey G, Matz K, Peeters A, Phillips S, Gubitz G, Prasad K, Ricci S, Celani MG, Righetti E, Cantisani T, Arauz A, Berge E, Slot KB, Kobayashi A, Czlonkowska A, Correia M, Murray V, Lyrer P, Venables G. EPITHET-where next? Lancet Neurol. 2008;7:570-571; author reply 1-3.
36. Butcher KS, Lee SB, Parsons MW, Allport L, Fink J, Tress B, Donnan G, Davis SM. Differential prognosis of isolated cortical swelling and hypoat-tenuation on CT in acute stroke. Stroke. 2007;38:941-947.
37. Donnan GA, Davis SM. Life after DIAS II. Int J Stroke. 2007;2:236-237.
38. Kidwell CS, Alger JR, Saver JL. Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke. 2003;34:2729-2735.
39. Hillis AE, Gold L, Kannan V, Cloutman L, Kleinman JT, Newhart M, Heidler-Gary J, Davis C, Aldrich E, Llinas R, Gottesman RF. Site of the ischemic penumbra as a predictor of potential for recovery of functions. Neurology. 2008;71:184-189.
40. Warach S. Stroke neuroimaging. Stroke. 2003;34:345-347.
41. Warach S. Measurement of the ischemic penumbra with MRI: it's about time. Stroke. 2003;34:2533-2534.
42. Albers GW. Advances in intravenous thrombolytic therapy for treatment of acute stroke. Neurology. 2001;57(suppl 2):S77-S81.
43. Abe O, Aoki S, Shirouzu I, Kunimatsu A, Hayashi N, Masumoto T, Mori H, Yamada H, Watanabe M, Masutani Y, Ohtomo K. MR imaging of ischemic penumbra. Eur J Radiol. 2003;46:67-78
44. SIGN. Management of patients with stroke or TIA: assessment, investigation, immediate management and secondary prevention. Scottish Intercollegiate Guidelines Network; 2008. Available from: www.sign.ac.uk/ pdf/sign108.pdf. Last accessed December 2008.
45. ESO-Guidelines for Management of Ischaemic Stroke 2008. Available at: http://www.eso-stroke.org/pdf/ESO08-Guidelines-English.pdf. Last accessed December 2008.
46. L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224-233.
47. Song F. Exploring heterogeneity in meta-analysis: is the L'Abbe plot useful? J Clin Epidemiol. 1999;52:725-730.
48. Schellinger PD, Fiebach JB, Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke. 2003;34: 575-583.